---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-25-000121"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2025-09-18T23:59:59+00:00"
generated_at: "2026-05-17T06:16:46.275251+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# GeneDx appoints Thomas Fuchs, SVP & Chief AI Officer at Lilly, as Class I director

## Summary
- Thomas Fuchs appointed to board effective September 17, 2025; board expands from 7 to 8 members.
- Dr. Fuchs serves as SVP and Chief AI Officer at Eli Lilly, leading AI for drug discovery and clinical trials.
- Initial RSU grant of $420,000 vesting over three years under non-employee director compensation policy.
- Dr. Fuchs holds a doctorate in machine learning from ETH Zurich and founded Paige AI.
- No transactions requiring disclosure under Item 404(a) and no arrangements with any person.

## SEC filing metadata
- accession: 0001818331-25-000121
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2025-09-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833125000121/0001818331-25-000121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833125000121/wgs-20250917.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-25-000121
- JSON: https://secwatch.observer/filing/0001818331-25-000121.json
- Plain text: https://secwatch.observer/filing/0001818331-25-000121.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.